Gonorrhea vaccine safety study
Part of Infections clinical trials.
This trial tests a new vaccine designed to protect against gonorrhea, a common sexually transmitted infection. The study checks how safe the vaccine is and how well it trains the immune system to fight the bacteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 50 years old.
- You are in good general health.
- You have never had gonorrhea before.
- You have never been vaccinated with Bexsero or another meningitis B vaccine.
- You are not pregnant or planning to become pregnant, and you are willing to use highly effective birth control if you can get pregnant.
- You can attend all follow-up visits and complete a diary of your symptoms.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at throat samples from people who may have been exposed to gonorrhea to better understand how the bacteria grow there. It may help improve testing and treatment for partners.
This trial tests a new meningitis vaccine (GNG-DE) to see how well it works compared to a vaccine already on the market. It might help protect you or your child from meningococcal disease.
This study evaluates a new rapid test for gonorrhea designed for women. You'll provide vaginal swab samples and complete a brief counseling session to help researchers understand how well the test works and whether patients can use it correctly.
This trial tests a new vaccine called DX-104 to see if it is safe and helps the body fight meningitis B. Healthy adults aged 18-50 can join to help find a better way to prevent this infection.
This study tests whether a new vaccine safely protects infants aged 6 to 11 months against four types of meningococcal bacteria that can cause serious infections like meningitis and blood infections. It is designed for healthy babies who have not yet received any meningococcal vaccine.
This trial tests a new two-part vaccine (CHO-V08) to prevent Klebsiella pneumoniae infection. It looks at safety and immune response in healthy adults aged 18 to 50.
Hear when a new Neisseria Gonorrhea trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.